- Home
- NAPA vs TVTX Comparison
NAPA vs TVTX Comparison
Compare NAPA & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAPA
- TVTX
- Stock Information
- Founded
- NAPA 1976
- TVTX 2008
- Country
- NAPA United States
- TVTX United States
- Employees
- NAPA N/A
- TVTX N/A
- Industry
- NAPA Beverages (Production/Distribution)
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- NAPA Consumer Staples
- TVTX Health Care
- Exchange
- NAPA Nasdaq
- TVTX Nasdaq
- Market Cap
- NAPA 1.6B
- TVTX 1.6B
- IPO Year
- NAPA 2021
- TVTX N/A
- Fundamental
- Price
- NAPA $11.08
- TVTX $17.41
- Analyst Decision
- NAPA Hold
- TVTX Buy
- Analyst Count
- NAPA 8
- TVTX 13
- Target Price
- NAPA $10.51
- TVTX $23.46
- AVG Volume (30 Days)
- NAPA 1.5M
- TVTX 1.1M
- Earning Date
- NAPA 12-05-2024
- TVTX 02-13-2025
- Dividend Yield
- NAPA N/A
- TVTX N/A
- EPS Growth
- NAPA N/A
- TVTX N/A
- EPS
- NAPA 0.39
- TVTX N/A
- Revenue
- NAPA $425,914,000.00
- TVTX $203,447,000.00
- Revenue This Year
- NAPA $22.74
- TVTX $62.17
- Revenue Next Year
- NAPA $6.79
- TVTX $56.38
- P/E Ratio
- NAPA $28.19
- TVTX N/A
- Revenue Growth
- NAPA 7.19
- TVTX 57.08
- 52 Week Low
- NAPA $5.38
- TVTX $5.12
- 52 Week High
- NAPA $11.10
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- NAPA 75.95
- TVTX 39.02
- Support Level
- NAPA $10.96
- TVTX $17.27
- Resistance Level
- NAPA $11.09
- TVTX $19.20
- Average True Range (ATR)
- NAPA 0.02
- TVTX 0.72
- MACD
- NAPA -0.04
- TVTX -0.29
- Stochastic Oscillator
- NAPA 83.33
- TVTX 3.80
About NAPA The Duckhorn Portfolio Inc.
The Duckhorn Portfolio Inc produces luxury and ultra-luxury wine across a portfolio of winery brands, including Duckhorn Vineyards, Paraduxx, Goldeneye, Migration, Decoy, Canvasback, Calera, Kosta Browne, Greenwing and Postmark. Its revenue is comprised of wholesale and direct-to-consumer sales. Wholesale revenue is generated through sales directly to California retailers and restaurants, sales to distributors and agents located in other states throughout the United States, and sales to export distributors that sell internationally.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.